Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Workforce
Biotech
Keros culls phase 2 PAH program, 70 staff roles
Keros is discontinuing development of its investigational TGF-β inhibitor in PAH after the asset missed the mark in both efficacy and safety.
Gabrielle Masson
May 29, 2025 10:10am
A look inside biopharma’s Q1: 8 closures and 63 layoff waves
Apr 1, 2025 9:00am
Roche mulls slashing 300 to 400 jobs in product development
Jul 1, 2021 10:25am
Diversity initiatives pick up across biotech but gaps persist
Jun 17, 2021 10:19am
Despite COVID-19, biotech internship program plots expansion
Apr 9, 2021 9:45am
Board diversity in U.K. life sciences: A 'stubborn challenge'
Feb 27, 2020 1:59pm
